Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) was upgraded by analysts at Zacks Research to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.
Several other brokerages have also weighed in on SCTX. Leerink Partners initiated coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective for the company. Wells Fargo & Company initiated coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price objective for the company. Guggenheim began coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $50.00 target price on the stock. Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Finally, HC Wainwright started coverage on Scribe Therapeutics in a research report on Monday. They issued a “buy” rating and a $60.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.
View Our Latest Report on SCTX
Scribe Therapeutics Stock Up 6.6%
Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last issued its quarterly earnings data on Wednesday, September 2nd. The company reported ($3.84) EPS for the quarter, topping analysts’ consensus estimates of ($6.20) by $2.36. Analysts forecast that Scribe Therapeutics will post -6.72 EPS for the current year.
Insider Activity
In other news, CFO David Parrot purchased 2,666 shares of Scribe Therapeutics stock in a transaction dated Thursday, July 23rd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the transaction, the chief financial officer directly owned 1,333 shares of the company’s stock, valued at approximately $19,995. This trade represents a -200.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. Following the acquisition, the insider owned 2,385,075 shares of the company’s stock, valued at approximately $35,776,125. This trade represents a 16.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 3,727,237 shares of company stock worth $56,291,746 in the last three months.
Trending Headlines about Scribe Therapeutics
Here are the key news stories impacting Scribe Therapeutics this week:
- Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
- Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
- Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
- Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
- Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
- Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.
About Scribe Therapeutics
Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.
Featured Articles
- Five stocks we like better than Scribe Therapeutics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
